Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tivozanib in Metastatic and Non-resectable Soft Tissue Sarcomas
NCT01782313Phase 2Completed
- Sponsor
- Northwestern University
- Start
- Mar 2013
- Primary completion
- May 2015
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tivozanib in soft tissue sarcoma (STS), sponsored by Northwestern University. Primary endpoint: Percentage of Patients With Progression-free Survival at 16 Weeks. Started Mar 2013; status: completed.
02
Drugs
tivozanib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT01782313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01782313.